Associations of ANKK1 (rs1800497) polymorphism with glucose and lipid metabolism in patients with schizophrenia treated with olanzapine: a retrospective study.

Abstract

Objective: Antipsychotic-induced metabolic disturbance (AIMD) represents a prevalent adverse effect associated with antipsychotic medications, with genetic factors partially contributing to the variability in susceptibility observed among patients with schizophrenia (SCZ). This study examined the effect of ANKK1 (rs1800497) polymorphism on glucose and lipid metabolism in Chinese patients diagnosed with SCZ and undergoing olanzapine treatment.

Methods: A cohort of 104 SCZ patients receiving olanzapine treatment was recruited retrospectively for the investigation. The polymorphism in the ANKK1 (rs1800497) gene were identified and analyzed. The clinical and demographic characteristics of subjects with ANKK1 (rs1800497) genotypes were compared at baseline. The associations between ANKK1 rs1800497 genotypes and glucose and lipid indicators at baseline were examined. Following a 4-week olanzapine treatment, changes in glucose and lipid indicators among subjects with ANKK1 (rs1800497) genotypes were evaluated. Additionally, the relationship between these genotypes and the alterations in glucose and lipid indicators after olanzapine treatment was analyzed.

Results: At baseline, individuals carrying the T allele of the ANKK1 rs1800497 polymorphism exhibited significantly lower serum total cholesterol (TC) levels compared to those possessing the CC genotype (P = 0.024). Moreover, under an additive allelic model (coded as 1 = CC, 2 = CT, 3 = TT), the TT genotype of the ANKK1 rs1800497 polymorphism demonstrated a negative correlation with serum TC (r = -0.237, P = 0.015) and glucose levels (r = -0.276, P = 0.005). Furthermore, following olanzapine treatment, patients who were carriers of the TT genotype of ANKK1 rs1800497 had a smaller reduction in glucose levels compared to those with the CC genotype (P = 0.027). Additionally, the TT genotype of the ANKK1 rs1800497 polymorphism demonstrated a positive correlation with changes in glucose levels (r = 0.237, P = 0.015).

Conclusion: These findings suggest a potential association between the ANKK1 rs1800497 polymorphism and blood glucose variability in Chinese patients with SCZ undergoing olanzapine treatment.